Progress of subclinical fracture of patients with acquired immune deficiency syndrome

doi:10.3877/cma.j.issn.1674-1358.2019.03.002

Abstract

Abstract:

With the wide application of anti-viral drugs for the treatment of acquired immune deficiency syndrome (AIDS), the life of patients with AIDS is nearly normal, and more and more studies showed that the application of high-efficiency combined anti-retroviral therapy (HAART) in patients with AIDS not only cause a brittle fracture of the osteoporosis, but also a significantly higher incidence of subclinical fracture of the vertebral body than that of the healthy people. The harm of the complication of HAART is gradually causing the attention of the clinician. This paper reviews the development of the definition, clinical diagnosis, epidemiology, mechanism and prevention and control measures of the subclinical fracture of the vertebral body in patients with AIDS.

Key words: Acquired immune deficiency syndrome, Subclinical fracture, Clinical diagnosis, Epidemiology, Occurrence mechanism, Prevention and control measures

Rui Ma, Qiang Zhang. Progress of subclinical fracture of patients with acquired immune deficiency syndrome[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(03): 181-184.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2019.03.002

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2019/V13/I03/181

References 38

[1]	Borderi M, Calza L, Colangeli V, et al. Prevalence of sub-clinical vertebral fractures in HIV-infected patients[J]. New Microbiol,2014,37(1):25-32.
[2]	Gazzola L, Savoldi A, Bai F, et al. Assessment of radiological vertebral fractures in HIV-infected patients: clinical implications and predictive factors[J]. HIV Med,2015,16(9):563-571.
[3]	Borderi M, Calza L, Colangeli V, et al. Prevalence of sub-clinical vertebral fractures in HIV-infected patients[J]. New Microbiol,2014,37(1):25-32.
[4]	Ilha TASH, Comim FV, Copes RM, et al. HIV and vertebral fractures: a systematic review and metanalysis[J]. Sci Rep,2018,8(1):7838.
[5]	Buckens CF, de Jong PA, WP Mali, et al. Prevalent vertebral fractures on chest CT: higher risk for future hip fracture[J]. J Bone Miner Res,2014,29(2):392-398.
[6]	Kanis J. Diagnosis of osteoporosis and assessment of fracturerisk[J]. Lancet,2002,359(9231):1929-1936.
[7]	Latika GU, Able LA, Sukesh ED, et al. Prevalence and predictors of asymptomatic vertebral fractures in inflammatory myositis[J]. Int J Rheum Dis,2018,21(3):725-731.
[8]	Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK[J]. Osteoporos Int,2008,19:385-397.
[9]	Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK[J]. Osteoporos Int,2008,19(10):1395-1408.
[10]	Calmy A, Chevalley T, Delhumeau C, et al. Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal women[J]. Osteoporos Int,2013,24(6):1843-1852.
[11]	Biver E, Calmy A, Delhumeau C, et al. Microstructural alterations of trabecular and cortical bone in long-term HIV-infected elderly men on successful antiretroviral therapy[J]. AIDS,2014,23,28(16):2417-2427.
[12]	Yin MT, Lund E, Shah J, et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life[J]. AIDS,2014,28(3):345-353.
[13]	Yin MT, Shu A, Zhang CA, et al. Trabecular and cortical microarchitecture in postmenopausal HIV-infected women[J]. Calcif Tissue Int,2013,92(6):557-565.
[14]	Silva BC, Leslie WD, Resch H, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image[J]. J Bone Miner Res,2014,29(3):518-530.
[15]	Silva BC, Broy SB, Boutroy S, et al. Fracture risk prediction by non-BMD DXA measures: the 2015 ISCD official positions Part 2: Trabecular Bone Score[J]. J Clin Densitom,2015,18(3):309-330.
[16]	Ulivieri FM, Silva BC, Sardanelli F, et al.Utility of the trabecular bone score (TBS) in secondary osteoporosis[J]. Endocrine,2014,47(2):435-448.
[17]	Lorenzo C, Pennica1 A, Argento JG, et al. Trabecular bone score (TBS) is associated with subclinical vertebral fractures in HIV infected patients[J]. Bone Miner Metab,2018,36:111-118.
[18]	Hoy J, Young B. Do people with HIV infection have a higher risk of fracture compared with those without HIV infection[J]. Curr Opin HIV/AIDS,2016,11(3):301-305.
[19]	Mccomsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers[J]. Clin Infect Dis,2010,51(8):937-946.
[20]	Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system[J]. J Clin Endocrinol Metab,2008,93(9):3499-3504.
[21]	王萍萍, 柯耀华, 张浩, 等. 绝经后妇女740例脆性骨折部位与骨密度关系的分析[J]. 中国科医学,2010,13(4):372-373.
[22]	Torti C, Mazziotti G, Soldini PA, et al. High prevalence of radiological vertebral fractures in HIV-infected males[J]. Endocrine,2012,41(3):512-7.
[23]	Borderi M, Calza L, Colangeli V, et al. Prevalence of sub-clinical vertebral fractures in HIV-infected patients[J]. New Microbiol,2014,37(1):25-32.
[24]	Moir S, Fauci AS. B cells in HIV infection and disease[J]. Nat Rev Immunol,2009,9(4):235-245.
[25]	Grigsby IFPL, Mansky LM, Gopalakrishnan R, et al. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss[J]. Biochem Biophys Res Commun,2010,394(1):48-53.
[26]	Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection[J]. AIDS,2009,23:1297-1310.
[27]	Calmy A, Staszewski S, Pozniak AL, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: A cross-sectional study[J]. J Infect Dis,2009,200(11):1746-1754.
[28]	Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial[J]. JAMA,2004,292(2):191-201．
[29]	Deeks SG. HIV infection, inflammation, immunosenecence, and aging[J]. Annu Rev Med,2011,62:141-155.
[30]	Wang L, Mondal D, La Russa VF, et al. Suppression of clonogenic potential of human bone marrow mesenchymal stem cells by HIV type 1: putative role of HIV type tat protein and inflammatory cytokines[J]. AIDS Res Hum Retroviruses,2002,18(13):917-931．
[31]	Albright P, Du P, Haas RE, et al. Evidence-based screening for low bone mineral density in HIV-infected men[J]. JANAC,2014,6(3):532-540.
[32]	Shahar E, Segal E, Rozen GS, et al. Vitamin D status in young HIV infected women of various ethnic origins: Incidence of vitamin D deficiency and possible impact on bone density[J]. Clinical Nutrition,2013,32(1):83-87.
[33]	Albright P, Du P, Haas RE, et al. Evidence-based screening for low bone mineral density in HIV-infected men[J]. J Assoc Nurses AIDS Care,2014,25(6):532-540.
[34]	Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000-2006[J]. Clin Infect Dis,2011,52(8):1061-1068.
[35]	Mayer KH, Amorosa V, Tebas P. Bone disease and HIV infection[J]. CID,2006,42(1):108-124.
[36]	Pinzone MR, Moreno S, Cacopardo B, et al. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis[J]. AIDS Rev,2014,16(4):213-222.
[37]	Johnell O, Amorosa V, Tebas P, et al. Associations between baseline risk factors and vertebral fracture risk in the multiple outcomes of raloxifene evaluation (MORE) study[J]. J Bone Miner Res,2004,19(5):764-772.
[38]	Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab[J]. Nat Rev Drug Discov,2012,11(5):4011-4119.

Please choose a citation manager

Content to export